Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback